Add a bookmark to get started


Pierre Queiroz De Oliveira

Of Counsel

Pierre is a registered patent attorney and concentrates his practice on strategic intellectual property counseling, patent preparation and prosecution, intellectual property procurement transactions, due diligence, and licensing matters.  Pierre has extensive experience in the pharmaceutical, biologic, nutraceutical, cosmetic, chemical, medical device fields.

Pierre holds a Ph.D in molecular pharmacology from the University of Pittsburgh School of Medicine where he conducted research on the effects of hypoxia on the cell cycle resulting in discovery of a novel regulatory mechanism for cancer progression.  Pierre has published his work in peer-reviewed journals including Nature Chemical Biology and had presented his work at national conferences.

Bar admissionsPennsylvaniaUnited States Patent and Trademark Office
CourtsUnited States District Court for the Western District of Pennsylvania


Product Exclusivity Strategies

  • Advised public and private companies on the creation and expansion of regulatory and patent exclusivity strategies to protect therapeutic products.
  • Formulated and deployed patent and regulatory strategies to maximize exclusivity for repurposed and repositioned drugs products.

Patent Prosecution and Strategic Counseling

  • Advised public commercial-stage regenerative medicine company on extending patent protection for its commercialized product.
  • Advised a private company focused on licensing, developing and commercializing antidotes for a variety of poisons.
  • Advised a private pharmaceutical company developing breakthrough therapies for urogenital conditions.
  • Advised a public drug discovery company developing small molecule therapies for neurological diseases.
  • Advised a private biopharmaceutical company with multiple, ongoing late-stage clinical development programs in neurosciences and dementia, rare diseases, dermatology and endocrinology.
  • Advised a private drug discovery company focused on the development of small molecule drugs capable of modulating protein stability.
  • Advised a biopharmaceutical company focused on the development of peptide-based therapeutics for the treatment of ocular disorders.
  • Advised a specialty pharmaceutical company focused on the development of therapeutics for neonatal and pediatric patients.
  • Advised multinational pharmaceutical company on patent preparation and prosecution of patents for pre-clinical oncology products.

IP Due Diligence and Transactions

  • Conducted IP due diligence in support of licensing efforts for public and private biotechnology companies.
  • Served as IP counsel for clinical-stage biopharmaceutical company in its US$45.2 million initial public offering.
  • Served as IP counsel for a commercial-stage regenerative medicine company in its US$50 million initial public offering.
  • Advised private biopharmaceutical company, conducting IP due diligence in support of strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies to augment its late-stage clinical development programs in neurosciences and dementia.
  • Advised a private early-stage drug discovery and development company in negotiating collaboration and license agreement with a global pharmaceutical company involving US$6 million in upfront payments and US$64 million in potential milestone payments.
  • Conducted internal IP due diligence reviews and audits on behalf of pharmaceutical, biopharmaceutical and medical device companies in preparation for partnering, financing and public offerings.
  • Provided counsel on and prepared nondisclosure agreements, consulting agreements, license agreements and collaboration/joint venture agreements for biotechnology companies.
  • J.D., Duquesne University
  • Ph.D., Pharmacology, University of Pittsburgh


  • Best Lawyers in America®: Ones to Watch: Intellectual Property Law (2024), Patent Law (2024), and Life Sciences Practice (2023 - 2024)
  • Recipient of the Pittsburgh Intellectual Property Association Student Leadership Award (2014)
  • CALI Award for Excellent achievement in the study of Commercial Use of Intellectual Property (2013)

Insight Overview

  • Co-author, "Aligning A Product's Marketing, Regulatory And IP Plans", Expert Analysis, Law360, September 8, 2017.
  • Co-author, Queiroz de Oliveira PE., Miller RA. Supreme Court affords greater leeway to biosimilars in the 'patent dance'; Pepper Hamilton LLP Client Alert, June 2017.
  • Speaker, "The BPCIA patent dance - what biosimilar companies need to know" CLE presentation through the Knowledge Group given on January 10, 2017
  • Naran et al. Bile salts differentially sensitize esophageal squamous cells to CD95 (Fas/Apo-1 receptor) mediated apoptosis. Journal of Surgical Research, December 2011.
  • Watson et al. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis. Neoplasia, March 2011.
  • De Oliveira et al. Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21.  Cell Cycle, October 2009.
  • Molina et al. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nature Chemical Biology, September 2009.
  • De Oliveira et al. Is a step backwards in S-phase-targeted chemotherapy a step forward? Molecular Interventions, June 2008.
  • Siegfried et al. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer. Molecular Pharmacology, September 2007.
  • Watson et al. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia, November 2006.
  • Lazo et al. Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1.  Bioorganic Medicinal Chemistry, August 2006.
  • Watson et al. Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma. Neoplasia, January 2006.
  • Mahidhara et al. Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma. Journal of Surgical Research, February 2005.
  • El-Hefnawy et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia, January 2005.